GlassScriptPhysician profile
Kelly Mann
NPI 1437671823
$7,366.37
in general payments reported to CMS, 2019-2025
18 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,780 · 2022: $1,341 · 2023: $1,230 · 2024: $1,458 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,245.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,511.82 | 2021-2025 | Proclaim, Eterna, Prodigy |
| Collegium Pharmaceutical, INC. | $856.69 | 2021-2025 | Belbuca, Xtampza, Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $845.46 | 2021-2025 | Relistor |
| Boston Scientific Corporation | $408.74 | 2024-2025 | Infinion 16, General - Therapies, Artisan |
| Forte Bio-Pharma LLC | $202.30 | 2022-2023 | Prolate, Nalocet |
| Scilex Pharmaceuticals INC. | $151.31 | 2021-2024 | Ztlido |
| Biodelivery Sciences International, INC. | $77.11 | 2021 | |
| Arbor Pharmaceuticals, INC. | $58.34 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $40.44 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $35.74 | 2021 | |
| Azurity Pharmaceuticals, INC. | $34.69 | 2023 | Horizant |
| Uswm, LLC | $27.21 | 2024 | Lucemyra |
| Pharmacosmos Therapeutics INC. | $23.79 | 2023 | Monoferric |
| Lilly USA, LLC | $22.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.40 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $19.28 | 2021 | |
| Amgen INC. | $16.67 | 2022 | |
| Redhill Biopharma INC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.